If you're shorting this stock don't be shocked when you get the Margin Call ..Many institutional investors foresee a upswing in PPS.. https://monreport.com/2019/03/01/synergy-pharmaceuticals-inc-sgyp-will-keep-adding-cash-to-your-wallet/ Synergy Pharmaceuticals Inc. is a component of the Russell 2000. The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.
That is ancient data. You need real time data. This world doesn’t stand still..
According to the latest 10-Q filing (click this link to view), as of 09/30/2018, they had Total Assets: $83M Total Liabilities: $179M Net loss in Q3'18 was: $34M
Can you be more specific on the "real-time" data you're talking about? Are you saying that SGYP has burned a lot more than the typical $34M/quarter in the last Q4(2018) even they're no longer running any clinical trials?
My estimate is that the $195M received from BHC should be more than enough to cover all debts/liabilities, and the $83M in cash/assets should be more than enough for covering all operating/legal expenses in the last 4 months, and after 03/05/2019 SGYP should still have over $50M value in asset and zero debt while retaining their core GI platform (uroguanylin).
Please back up with real data rather than just making those baseless/unsubstantial claims.
News 
Market Data 
Discover 
